METHODS
We retrospectively reviewed the medical records of pediatric patients
treated at the Dana-Farber/Boston Children’s (DF/BC) Cancer and Blood
Disorders Center with the VDC-ICE treatment plan and diagnosed from
January 2006 to December 2016. Patients were identified through a search
of the Pediatric Patient Informatics Platform and electronic
chemotherapy order entry reports detailing treatment plans. These
reports were reviewed for their accuracy. Patients were excluded if –
despite receiving a recommendation for this treatment plan or beginning
this treatment plan at DF/BC – they completed the bulk of the treatment
at another institution or had shared cared with another institution, as
all details on toxicity were not available. General characteristics of
these patients were captured as available but were not included in the
analysis. Data collected on the population of interest included patient
demographics, treatment plan, and clinical course, as well as
complications, toxicities, and outcomes. This study was approved by the
Dana-Farber Cancer Institute Institutional Review Board.